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ABSTRACT 
Objective: Cordyceps militaris is an entomopathogen and known to exhibit significant therapeutic potential. In the present study, we aimed to 
extract various fractions (aqueous; hexane; chloroform & butanol) including active ingredient cordycepin from fermented broth of Cordyceps 
militaris followed by their evaluation as anti-angiogenic agents.  
Methods: The bioactive metabolite, cordycepin and various Cordyceps derived fractions were isolated from liquid culture of Cordyceps militaris 
using solvent-solvent extraction method followed by purification on silica gel column chromatography. Furthermore anti-angiogenic properties of 
extracted fermentation broth were also investigated using chorioallantoic membrane (CAM) assay.  
Results: Butanolic fractions, demonstrated the highest anti-angiogenic activity followed by chloroform, hexane and aqueous fractions of extracted 
fermentation broth. Anti-angiogenic studies for extracted cordycepin showed that 40 µg/egg dosage of cordycepin was sufficient to inhibit the 
branching of blood vessels significantly (~50%) in a CAM assay.  
Conclusion: It is concluded that butanolic extract/cordycepin from fermented broth of Cordyceps militaris potentially inhibits the angiogenesis and 
suggests that the inhibition of angiogenesis is one of the mechanisms by which Cordyceps militaris can mediate an anti-cancer effect. 
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Angiogenesis is a complex and tightly controlled physiological 
process by which new blood vessels are originated from pre-existing 
capillaries. Angiogenesis plays an important role in physiological 
and pathological processes such as wound healing, placentation, 
embryo-genesis, diabetic retinopathy, inflammatory disorders and 
tumor growth [1, 2]. Tumor cells can induce angiogenesis through 
the activation of endothelial cells followed by pro-angiogenic factors 
such as vascular endothelial growth factor (VEGF), fibroblast growth 
factor (FGF) and epidermal growth factor (EGF) [3-5]. These factors 
are highly expressed and associated with growth of various types of 
human tumors [6, 7]. Therefore, compounds with anti-angiogenic 
properties have been identified as an attractive strategy for the 
treatment and prevention of cancer. Researchers have been trying to 
screen novel herbal preparations with anti angiogenic potential.  
INTRODUCTION 
Cordyceps militaris is an entomopathogenic fungus, with variety of 
clinical health effects including immunomodulatory, anticancer, 
antioxidant, anti-inflammatory and anti-microbial activities [8, 9]. 
Due to specific distribution and potent medicinal value, the market 
price of Cordcyeps species costs about US$ 12000 kg-1
Cordycepin is a kind of nucleoside analogue having structural 
similarity with adenosine, except that it lacks 3’ hydroxyl group 
which makes it more potent and 
 [10]. 
Cordyceps militaris have been known to produce a variety of 
pharmacologically active compounds like cordycepin, adenosine, 
cordymin and exo-polysaccharides [8, 11, 12].  
known to interfere with various 
biochemical and molecular processes including purine biosynthesis 
[13, 14], DNA/RNA synthesis [15] and mTOR (Mammalian Target of 
Rapamycin) signaling transduction etc. [16, 17]. Efforts have been 
made to artificially cultivate this mushroom by solid and submerged 
fermentation techniques. The solid culture of mushroom takes long 
time to complete fruiting body whereas liquid submerge culture is 
preferred to produce desired bio-metabolite (cordycepin). To 
overcome such limitations, researchers tried submerged 
fermentation for the production of cordycepin on commercial scale. 
In this study, the extracted fermentation broth of Cordyceps militaris 
was used to investigate the anti-angiogenic activity.  
MATERIALS AND METHODS 
Chemicals and microbial strain  
Standard Cordycepin (3’-deoxyadenosine) was purchased from 
Sigma Chemical Corporation (St. Louis, MO, USA). Other chemicals 
and nutrient medium ingredients of analytical grade were purchased 
from E-Merck India and Hi media Ltd (India) respectively. Cordyceps 
militaris 3936 was procured from microbial type culture collection 
(MTCC) IMTECH, Chandigarh, India which was regularly maintained 
on potato dextrose agar (PDA) slants and stored at 4°C.  
Inoculum preparation and fermentation 
Cordyceps militaris 3936 was initially grown on PDA medium in a 
petri dish and then transferred to the seed culture medium by 
punching out 5 mm of the agar plate culture with a sterilized cork 
borer. The seed culture was grown in a 250-mL flask containing 50 
mL of basal medium (glucose 15 g L-1, peptone 5 g L-1, KH2PO4 3 g L-
1, K2HPO4 1 g L-1) at 25 °C on a rotary shaker incubator at 150 rpm 
for 4 days. The batch mode fermentation experiments were performed 
in a 1000-mL flask containing 500-mL of the media with 4% (v/v) 
inoculums of the seed culture.
Extraction, isolation and identification of cordycepin 
 The inoculated bottles were initially 
incubated at 25°C for 7 days in stationary phase then transferred to 
shaking mode for 10 days followed by again stationary condition for 7 
days. 
Fermented broth filtered and filtrate was concentrated up to 1/20th 
volume in vacuum evaporator at a temperature below 50°C, which 
resulted in dark brown syrup. The crude material was extracted 
sequentially from non-polar to polar solvents by hexane, chloroform 
and n-butanol. The presence of cordycepin was confirmed in 
butanolic fraction by TLC, Spectrophotometric and HPLC studies. 
Further the butanol soluble fraction was subjected to repeated silica 
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gel column chromatography to get purify cordycepin. The obtained 
cordycepin was confirmed using UV, HPLC and NMR techniques. 
Thin layer plates (10 × 20 cm) of silica gel GF 254, thickness 0.25 
mm were prepared and placed under hot air oven to evaporate 
solvent. TLC plates were developed in chloroform/ methanol/water 
(64:14:1) and compounds were visualized in UV chamber at 260nm 
or by spraying 10 % H
Thin Layer Chromatography for cordycepin detection 
2SO4 in ethanol followed by heating on hot 
plates [18]. 
The compound was scratched out from TLC plates and quantified 
using spectrophotometric assay at 460nm which is based on 
cordycepin reaction with anthrone, resulted in production of cherry 
red color [19]. Reagent was prepared by dissolving 0.2 gm anthrone 
in 100 ml of 90 % H
Spectro photometric assay for quantitative estimation of 
cordycepin 
2SO4
Chorioallantoic membrane assay 
.  
Anti-angiogenic properties of Cordyceps derived fractions and 
cordycepin were evaluated using modified Chorioallantoic 
membrane assay (CAM) [20]. The fertilized chicken egg was 
collected on 0th 
 
day, cleaned with 70% ethanol to avoid infections 
and kept in a humidified (70%) chamber at 37°C. After 48 h, 2 ml of 
albumin was taken with a syringe at the lower side of the egg and 
the pierced hole was sealed with a sterilized laboratory tape (Fig. 1). 
This procedure allows separation of the intact, non injured CAM 
from the shell during the embryo development which is an 
important issue because any injury to the CAM may alter the potency 
of test sample. At 72 h of incubation, a small window was created by 
removing the egg shell at the blunt end. After confirmation normal 
and viable development of the embryo, various fractions (Hex, chl, 
BuOH and aq) of Cordyceps and cordycepin were introduced on 5 
mm sterile filter discs and placed over the surface of extra 
embryonic membrane i.e. CAM. The window was sealed with sterile 
laboratory tape so as to prevent external environmental contact. On 
completion of another 48 h, potency of Cordyceps fractions and 
isolated cordycepin, as anti angiogenic agents were calculated in 
terms of inhibition of blood vessels branch points with comparison 
to control. All experiments were conducted at least in triplicate to 
confirm the results.  
 
Fig. 1: (a) procurement of 0th
 
 day eggs and incubated in BOD 
incubator. (b) Aspiration of 2 ml albumin from lower end after 
24 h incubation. (c) Development of CAM with visible blood 
vessels after 72 h of incubation. 
Quantification of angiogenesis 
The CAM at the site of application for angiogenesis was examined 
with comparison to control. After 48h of treatment, anti angiogenic 
effect of Cordyceps fractions was manually counted in terms of 
branch points over CAM and calculated the percent inhibition as 
follows.  
% Inhibition = Data of control – Data of treated X 100 / Data of 
control 
RESULTS 
Purification of cordycepin 
In this study, the fermented broth of Cordyceps militaris was 
extracted with various solvents such as hexane, chloroform and 
butanol. Cordycepin was detected in butanolic fractions using 
various identification tools such as TLC, spectrophotometer and 
HPLC.  
The butanolic portion was eluted on silica gel column with stepwise 
gradient of methanol: chloroform (5:95, 15:85, 25:75, 35:65, 45:55 
and 55:45) and six fractions were obtained (F1-F6). Presence of 
cordycepin was found in fraction F2 by TLC which was sub-
fractionated into four fractions (S1-S4) using elution gradient 
methanol: chloroform (15:85). Sub fraction S3 was found to carry 
cordycepin which was further vacuum dried and recrystallized in 
methanol giving a white/creamy powdery product. Spectral analysis 
of purified cordycepin was performed using UV, HPLC and NMR 
spectroscopy and the data is consistent with our earlier published 
values [21]. We performed the CAM assay to examine the effect of 
cordycepin/ Cordyceps fractions on angiogenesis. 
We prepared various Cordyceps fractions by partitioning crude 
extract, sequentially from non polar to polar solvents such as 
hexane, chloroform, n-butanol. The collected fractions were dried 
under vacuum and studied for their anti-angiogenic activity at a dose 
of 100µg/disc. The significant differences were found among the 
various fractions (Hex, Ch, BuOH) and BuOH fraction comes out to be 
potent inhibitor of angiogenesis in the chicken embryos with 
comparison to untreated control. Furthermore, the anti-angiogenic 
effect of extracted cordycepin was also studied at various 
concentrations such as 10, 20, 40, 60 & 80µg/egg. Our results 
revealed that, 40 µg/egg doses was sufficient to inhibit branching of 
blood vessel up to 50% and found to be more potent than any 
extracted fractions of Cordyceps (Fig. 2 &3).  
Chorioallantoic membrane assay 
 
Fig. 2: Effect of Cordyceps derived fractions and cordycepin on 
angiogenesis. CAM were treated with various fractions Aq, Hex, 
Ch & BuOH at 100µg/egg and also with different concentrations 
of purified cordycepin. Control CAM treated with papper disc 
without drug. All the experiment was conducted in triplicates 
and data represented the average of three replicate. 
 
Fig. 3: (a) The photograph showed the anti-angiogenic activity 
of Cordyceps militaris extracted fraction (Aq = Aqueous; Hex = 
Hexane; Ch = Chloroform and BuOH = Butanol). b) The effect of 
purified cordycepin on angiogenesis at various concentrations 
(10, 20, 40, 60 and 80 µg/egg). 
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DISCUSSION 
Cordyceps militaris has been used as a traditional Chinese medicine 
mushroom for the treatment of many diseases including cancer 
complications. On the other hand, cancer growth and metastasis are 
intimately related with angiogenesis [17, 22]. Due to this reason, 
anti-angiogenesis has been a focus in cancer research, and several 
clinical drugs have been used with satisfactory effects [23]. However 
some of antitumor and antiangiogenis activities of Cordyceps 
militaris crude extracts have been studied [24-28]. Though, its active 
compound, cordycepin have not been fully explored from the anti-
angiogenic point of view. In this report, we investigated first time 
the inhibitory effects of fermentation broth of C. militaris 3936 on 
angiogenesis using CAM assay. CAM is one of the most widely used 
in vivo vessel development model [29]. The result of CAM assay 
showed that Cordyceps had the potential anti-angiogenic function. 
We isolated and identified a bioactive metabolite, cordycepin from 
Cordyceps militaris 3936. The Cordyceps derived fractions and 
cordycepin displayed anti-angiogenic and antimicrobial activity. Out 
of four Cordyceps derived fractions (Aq, Hex, Ch and BuOH), the 
BuOH fraction showed the highest inhibitory activity in angiogenic 
response, followed by Ch, Hex and then aqueous. However the active 
ingredient, cordycepin was even more effective than other fractions 
as anti-angiogenic agent.  
CONCLUSION 
This study found the anti-angiogenic activity of extracted 
fermentation broth of Cordyceps militaris. We observed that anti-
angiogenic activity is directly correlated with the content of 
cordycepin in the Cordyceps derived fractions. We suggest that the 
inhibition of angiogenesis is one of the mechanisms by which 
Cordyceps militaris can mediate an anti-cancer effect. However, 
further studies are required to elucidate the exact mechanism 
underlying the anti-angiogenic property of Cordyceps. Further 
investigation is in progress in our laboratory to isolate other 
individual components which are present in Cordyceps extracts 
using modern chromatography techniques. 
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